Biochemical effects and drug levels in rats after long-term treatment with the specific 5-HT-uptake inhibitor, citalopram - PubMed (original) (raw)

• PMID: 6429698
• DOI: 10.1007/BF00427416

Biochemical effects and drug levels in rats after long-term treatment with the specific 5-HT-uptake inhibitor, citalopram

J Hyttel et al. Psychopharmacology (Berl). 1984.

Abstract

The effects in rats of long-term administration of the potent, specific 5-HT uptake inhibitor citalopram have been investigated. Citalopram hydrobromide (MW = 405) was given in the diet, 99 or 25 mumol/kg daily, for 13 days or orally, 49 mumol/kg twice a day, for 14 days. High plasma and brain levels of citalopram were found during the treatment period, whereas negligible amounts were found 24 h after withdrawal. The 5-HT uptake mechanism in blood platelets was completely blocked, since levels of whole blood 5-HT during and shortly (2 days) after treatment were decreased by 75-90%. The drug load after the two highest doses in terms of plasma drug levels was the same as in depressed patients treated with citalopram. Receptor binding technique ex vivo was applied to different brain parts to measure receptor parameters for several neurotransmitters. All data were evaluated by Eadie- Hoffstee analysis. No changes were seen in Bmax and Kd for beta-receptors (3H-dihydroalprenolol) in frontal cortex, occipital + temporal cortex, whole cortex and limbic structures, 5-HT2 receptors (3H-spiroperidol) in frontal and whole cortex, alpha 1-receptors (3H-prazosin) in "rest of brain" and DA D-2 receptors (3H-spiroperidol) in corpus striatum and limbic structures. The uptake mechanism for 5-HT as well as the inhibitory effect of citalopram on this uptake remained unaffected in brain synaptosomes derived from control and from citalopram (99 mumol/kg)-treated rats. Thus long-term treatment with citalopram does not induce changes in neurotransmitter receptors as seen with most tricyclic as well as newer " atypical " antidepressants.(ABSTRACT TRUNCATED AT 250 WORDS)

PubMed Disclaimer

Similar articles

• Changes in rat dopamine- and serotonin function in vivo after prolonged administration of the specific 5-HT uptake inhibitor, citalopram.
  Arnt J, Overø KF, Hyttel J, Olsen R. Arnt J, et al. Psychopharmacology (Berl). 1984;84(4):457-65. doi: 10.1007/BF00431450. Psychopharmacology (Berl). 1984. PMID: 6441945
• Prolonged treatment with the specific 5-HT-uptake inhibitor citalopram: effect on dopaminergic and serotonergic functions.
  Arnt J, Hyttel J, Overø KF. Arnt J, et al. Pol J Pharmacol Pharm. 1984 Mar-Jun;36(2-3):221-30. Pol J Pharmacol Pharm. 1984. PMID: 6591152
• Effect of a specific 5-HT uptake inhibitor, citalopram (Lu 10-171), on 3H-5-HT uptake in rat brain synaptosomes in vitro.
  Hyttel J. Hyttel J. Psychopharmacology (Berl). 1978 Dec 15;60(1):13-8. doi: 10.1007/BF00429172. Psychopharmacology (Berl). 1978. PMID: 104340
• The citalopram/5-HTP-induced head shake syndrome is correlated to 5-HT2 receptor affinity and also influenced by other transmitters.
  Arnt J, Hyttel J, Larsen JJ. Arnt J, et al. Acta Pharmacol Toxicol (Copenh). 1984 Nov;55(5):363-72. doi: 10.1111/j.1600-0773.1984.tb01996.x. Acta Pharmacol Toxicol (Copenh). 1984. PMID: 6152104
• Citalopram--pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity.
  Hyttel J. Hyttel J. Prog Neuropsychopharmacol Biol Psychiatry. 1982;6(3):277-95. doi: 10.1016/s0278-5846(82)80179-6. Prog Neuropsychopharmacol Biol Psychiatry. 1982. PMID: 6128769 Review.

Cited by

• Clozapine modulates retinoid homeostasis in human brain and normalizes serum retinoic acid deficit in patients with schizophrenia.
  Regen F, Cosma NC, Otto LR, Clemens V, Saksone L, Gellrich J, Uesekes B, Ta TMT, Hahn E, Dettling M, Heuser I, Hellmann-Regen J. Regen F, et al. Mol Psychiatry. 2021 Sep;26(9):5417-5428. doi: 10.1038/s41380-020-0791-8. Epub 2020 Jun 2. Mol Psychiatry. 2021. PMID: 32488128 Free PMC article.
• Drug-drug conditioning between citalopram and haloperidol or olanzapine in a conditioned avoidance response model: implications for polypharmacy in schizophrenia.
  Sparkman NL, Li M. Sparkman NL, et al. Behav Pharmacol. 2012 Oct;23(7):658-68. doi: 10.1097/FBP.0b013e328358590d. Behav Pharmacol. 2012. PMID: 22903071 Free PMC article.
• Chronic citalopram treatment elevates serotonin synthesis in flinders sensitive and flinders resistant lines of rats, with no significant effect on Sprague-Dawley rats.
  Kanemaru K, Nishi K, Hasegawa S, Diksic M. Kanemaru K, et al. Neurochem Int. 2009 May-Jun;54(5-6):363-71. doi: 10.1016/j.neuint.2009.01.005. Neurochem Int. 2009. PMID: 19418630 Free PMC article.
• In vivo steady-state pharmacokinetic outcome following clinical and toxic doses of racemic citalopram to rats.
  Kugelberg FC, Apelqvist G, Carlsson B, Ahlner J, Bengtsson F. Kugelberg FC, et al. Br J Pharmacol. 2001 Apr;132(8):1683-90. doi: 10.1038/sj.bjp.0704015. Br J Pharmacol. 2001. PMID: 11309239 Free PMC article.
• Citalopram--a review of pharmacological and clinical effects.
  Bezchlibnyk-Butler K, Aleksic I, Kennedy SH. Bezchlibnyk-Butler K, et al. J Psychiatry Neurosci. 2000 May;25(3):241-54. J Psychiatry Neurosci. 2000. PMID: 10863884 Free PMC article. Review.

References

1. 1. Psychopharmacology (Berl). 1979 Jun 21;63(3):199-202 - PubMed
2. 1. Science. 1980 Oct 3;210(4465):88-90 - PubMed
3. 1. Acta Pharmacol Toxicol (Copenh). 1981 Jan;48(1):53-60 - PubMed
4. 1. Eur J Pharmacol. 1976 May;37(1):1-11 - PubMed
5. 1. Life Sci. 1982 Apr 26;30(17):1407-22 - PubMed

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Springer